Remus Pharmaceuticals Ltd (REMP)

Currency in INR
883.70
+34.70(+4.09%)
Closed·

REMP Financial Summary

Key Ratios

P/E Ratio28.39
Price/Book2.19
Debt / Equity8.13%
Return on Equity19.86%
Dividend Yield0.11%
EBITDA456.90M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 32.61%
Dividend Yield
0.11%
Industry Median 0.74%
Annualised payout
1.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 17, 2025
EPS / Forecast
49.80 / --
Revenue / Forecast
3.48B / --
EPS Revisions
Last 90 days

FAQ

What were Remus Pharmaceuticals's earnings for the latest quarter?

The Remus Pharmaceuticals EPS (TTM) is 32.61. Remus Pharmaceuticals reported sales of 3,476.76, net income of 150.59, and EPS of 49.80 for the latest quarter.

What was Remus Pharmaceuticals's net income for the latest quarter?

Remus Pharmaceuticals's net income for the latest quarter was 150.59.

How did Remus Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 2,726.85 in the previous quarter to 3,476.76 in the latest quarter, and net income moved from 140.11 to 150.59 compared to the previous quarter.

What is Remus Pharmaceuticals's net profit margin on a TTM basis?

Remus Pharmaceuticals's trailing twelve months (TTM) net profit margin is 4.69%.

How does Remus Pharmaceuticals's debt to equity ratio compare to industry standards?

Remus Pharmaceuticals's total debt-to-equity ratio is 8.13%.

What is Remus Pharmaceuticals's return on investment on a TTM basis?

Remus Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is 19.86%.

Did Remus Pharmaceuticals gain or lose cash last quarter?

In the latest quarter, Remus Pharmaceuticals's net change in cash was -166.25 million.

What were Remus Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Remus Pharmaceuticals reported total assets of 4,326.40 million and total liabilities of 1,215.30 million.

How has Remus Pharmaceuticals's total revenue grown this year?

Remus Pharmaceuticals's total revenue was 2,726.85 in the previous quarter and 3,476.76 in the latest quarter.

What is Remus Pharmaceuticals's gross margin on a TTM basis?

Remus Pharmaceuticals's trailing twelve months (TTM) gross margin is 14.10%.

What was Remus Pharmaceuticals's revenue per share for the latest quarter?

Remus Pharmaceuticals's revenue per share for the latest quarter was 301.41.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.